donepezil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	946	120014-06-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: aricept donepezil donepezil hydrochloride donepezil HCl donezpil hydrochloride donezpil donezpil HCl donepezilium oxalate trihydrate donepezilium oxalate donepezil oxalate E2020 E-2020	An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE. Molecular weight: 379.50 Formula: C24H29NO3 CLOGP: 4.40 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 38.77 ALOGS: -4.93 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

aricept
donepezil
donepezil hydrochloride
donepezil HCl
donezpil hydrochloride
donezpil
donezpil HCl
donepezilium oxalate trihydrate
donepezilium oxalate
donepezil oxalate
E2020
E-2020

An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.

Molecular weight: 379.50
Formula: C24H29NO3
CLOGP: 4.40
LIPINSKI: 0
HAC: 4
HDO: 0
TPSA: 38.77
ALOGS: -4.93
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
7.50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	10.60 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.38 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Nov. 25, 1996	FDA	EISAI INC
Dec. 23, 2022	PMDA	Teikoku Seiyaku Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bradycardia	631.23	13.55	427	33815	72800	63381980
Fall	469.91	13.55	792	33450	391542	63063238
Syncope	417.25	13.55	408	33834	116977	63337803
Dementia	311.41	13.55	167	34075	18627	63436153
Sinus bradycardia	286.01	13.55	145	34097	14406	63440374
Electrocardiogram QT prolonged	267.48	13.55	236	34006	59294	63395486
Drug interaction	237.44	13.55	435	33807	228696	63226084
Hallucination	210.42	13.55	199	34043	54618	63400162
Confusional state	195.25	13.55	408	33834	235972	63218808
Torsade de pointes	194.52	13.55	109	34133	13242	63441538
Aggression	180.87	13.55	128	34114	23370	63431410
Agitation	179.68	13.55	190	34052	59567	63395213
Delusion	153.36	13.55	90	34152	11927	63442853
Cognitive disorder	152.96	13.55	169	34073	55646	63399134
Parkinsonism	151.46	13.55	85	34157	10354	63444426
Neuroleptic malignant syndrome	142.66	13.55	86	34156	11970	63442810
Abnormal behaviour	131.81	13.55	102	34140	21324	63433456
Delirium	129.86	13.55	148	34094	50393	63404387
Drug ineffective	127.23	13.55	232	34010	1044533	62410247
Seizure	124.90	13.55	242	34000	132392	63322388
Pleurothotonus	117.03	13.55	39	34203	1310	63453470
Sinus node dysfunction	113.92	13.55	54	34188	4631	63450149
Muscle rigidity	110.79	13.55	72	34170	11428	63443352
Somnolence	110.19	13.55	275	33967	178410	63276370
Atrioventricular block first degree	107.62	13.55	60	34182	7213	63447567
Hallucination, visual	106.10	13.55	86	34156	19212	63435568
Pain	105.44	13.55	148	34094	740480	62714300
Arthralgia	105.00	13.55	92	34150	569618	62885162
Urinary retention	101.23	13.55	102	34140	30199	63424581
Hypersensitivity	101.06	13.55	18	34224	292667	63162113
Tremor	99.46	13.55	220	34022	132019	63322761
Altered state of consciousness	97.53	13.55	92	34150	25138	63429642
Amyloid related imaging abnormality-oedema/effusion	96.93	13.55	22	34220	162	63454618
Extrapyramidal disorder	94.50	13.55	69	34173	13215	63441565
Joint swelling	93.84	13.55	30	34212	327636	63127144
Systemic lupus erythematosus	92.27	13.55	5	34237	208913	63245867
Cholinergic syndrome	92.16	13.55	26	34216	492	63454288
Loss of consciousness	91.64	13.55	199	34043	117922	63336858
Femoral neck fracture	91.15	13.55	57	34185	8466	63446314
Rash	88.04	13.55	104	34138	560767	62894013
Infusion related reaction	87.17	13.55	14	34228	245507	63209273
Dehydration	85.82	13.55	246	33996	173108	63281672
Arthropathy	84.23	13.55	13	34229	234779	63220001
Electrocardiogram PR prolongation	83.56	13.55	26	34216	698	63454082
Decreased appetite	81.80	13.55	309	33933	250743	63204037
Myoclonus	81.55	13.55	68	34174	15800	63438980
Alopecia	80.22	13.55	41	34201	337495	63117285
Rheumatoid arthritis	78.63	13.55	20	34222	253799	63200981
Hypokalaemia	78.37	13.55	173	34069	103631	63351149
Depressed level of consciousness	77.27	13.55	128	34114	61950	63392830
Glossodynia	76.80	13.55	5	34237	178871	63275909
Pemphigus	76.39	13.55	6	34236	183720	63271060
Drug intolerance	75.60	13.55	36	34206	308625	63146155
Torticollis	74.97	13.55	31	34211	1918	63452862
Swelling	74.02	13.55	28	34214	275350	63179430
Hypothermia	73.55	13.55	60	34182	13521	63441259
Lethargy	73.11	13.55	118	34124	55889	63398891
Nightmare	72.29	13.55	69	34173	19125	63435655
Sinusitis	71.87	13.55	17	34225	226636	63228144
Dementia Alzheimer's type	70.03	13.55	25	34217	1035	63453745
Treatment failure	69.19	13.55	12	34230	199031	63255749
Mania	67.74	13.55	55	34187	12312	63442468
Immobile	66.73	13.55	41	34201	5902	63448878
Hypophagia	66.22	13.55	83	34159	31176	63423604
Mental status changes	63.79	13.55	92	34150	39507	63415273
Urinary incontinence	63.08	13.55	82	34160	31932	63422848
Urinary tract infection	60.77	13.55	293	33949	264391	63190389
Pericarditis	58.54	13.55	3	34239	131576	63323204
Disorientation	58.27	13.55	88	34154	39364	63415416
Therapeutic product effect decreased	56.48	13.55	17	34225	193170	63261610
Dyskinesia	55.46	13.55	77	34165	31925	63422855
Drug hypersensitivity	54.91	13.55	52	34190	310635	63144145
Atrioventricular block complete	54.52	13.55	41	34201	8210	63446570
Restlessness	54.26	13.55	73	34169	29380	63425400
Sudden death	54.15	13.55	45	34197	10404	63444376
Hyponatraemia	52.63	13.55	156	34086	111744	63343036
Unresponsive to stimuli	52.19	13.55	77	34165	33739	63421041
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits	51.15	13.55	11	34231	61	63454719
Gastrointestinal haemorrhage	51.07	13.55	126	34116	81050	63373730
Cerebral infarction	49.90	13.55	63	34179	23830	63430950
Wandering pacemaker	49.66	13.55	8	34234	3	63454777
Reduced facial expression	48.84	13.55	23	34219	1943	63452837
Medication error	48.65	13.55	95	34147	52189	63402591
Abdominal discomfort	48.64	13.55	61	34181	320824	63133956
Lower respiratory tract infection	48.17	13.55	7	34235	132300	63322480
Dizziness	47.14	13.55	394	33848	429531	63025249
Anal incontinence	45.88	13.55	46	34196	13530	63441250
Encephalopathy	45.86	13.55	78	34164	38542	63416238
Apathy	45.83	13.55	38	34204	8756	63446024
Off label use	45.13	13.55	199	34043	674263	62780517
Sexually inappropriate behaviour	45.02	13.55	11	34231	115	63454665
Hypocapnia	44.95	13.55	14	34228	377	63454403
Circulatory collapse	44.48	13.55	57	34185	21881	63432899
Pain in extremity	44.27	13.55	69	34173	331417	63123363
Pneumonia aspiration	44.01	13.55	72	34170	34468	63420312
Hypotension	43.83	13.55	274	33968	272330	63182450
Psychomotor hyperactivity	43.35	13.55	40	34202	10623	63444157
Hip fracture	42.47	13.55	65	34177	29409	63425371
Cerebral atrophy	42.25	13.55	29	34213	5037	63449743
Infection	42.08	13.55	37	34205	229136	63225644
Pruritus	41.26	13.55	83	34159	361370	63093410
Listless	40.70	13.55	23	34219	2837	63451943
Hepatic enzyme increased	40.48	13.55	30	34212	202298	63252482
Death	40.42	13.55	342	33900	374039	63080741
Wound	39.99	13.55	19	34223	163244	63291536
Fracture	39.89	13.55	51	34191	19533	63435247
Febrile neutropenia	39.31	13.55	8	34234	118441	63336339
Generalised tonic-clonic seizure	39.04	13.55	62	34180	28954	63425826
Miosis	38.80	13.55	32	34210	7321	63447459
Dementia with Lewy bodies	38.43	13.55	12	34230	326	63454454
Weight increased	38.03	13.55	51	34191	260741	63194039
Psoriatic arthropathy	37.99	13.55	3	34239	91517	63363263
Accidental overdose	37.31	13.55	54	34188	23255	63431525
Tardive dyskinesia	36.73	13.55	33	34209	8469	63446311
Epilepsy	36.64	13.55	58	34184	27007	63427773
Gait disturbance	36.52	13.55	195	34047	182983	63271797
Rhabdomyolysis	36.29	13.55	76	34166	43875	63410905
Stomatitis	35.77	13.55	15	34227	138710	63316070
Neuropsychiatric symptoms	35.62	13.55	14	34228	759	63454021
Dysarthria	35.43	13.55	74	34168	42637	63412143
Long QT syndrome	35.24	13.55	22	34220	3257	63451523
Nasopharyngitis	34.81	13.55	52	34190	254205	63200575
Atrial fibrillation	34.19	13.55	139	34103	116497	63338283
Impaired healing	33.87	13.55	7	34235	102535	63352245
Sialoadenitis	33.83	13.55	17	34225	1655	63453125
Atrioventricular block	33.66	13.55	30	34212	7617	63447163
Irritable bowel syndrome	33.39	13.55	3	34239	82409	63372371
Incontinence	33.19	13.55	36	34206	11596	63443184
Intentional product use issue	32.70	13.55	14	34228	127878	63326902
Lack of spontaneous speech	32.43	13.55	9	34233	160	63454620
Hypoglycaemia	32.38	13.55	88	34154	59977	63394803
Discomfort	31.97	13.55	26	34216	167348	63287432
Cerebrovascular accident	31.87	13.55	129	34113	107895	63346885
Headache	31.66	13.55	206	34036	633035	62821745
Dropped head syndrome	31.43	13.55	9	34233	180	63454600
Pelvic fracture	30.78	13.55	37	34205	13311	63441469
Fatigue	30.68	13.55	319	33923	887709	62567071
Upper gastrointestinal haemorrhage	30.64	13.55	44	34198	18808	63435972
Neuroglycopenia	30.55	13.55	11	34231	467	63454313
Therapeutic product effect incomplete	29.94	13.55	15	34227	125041	63329739
Paratonia	29.92	13.55	6	34236	22	63454758
Wrong patient received product	29.40	13.55	17	34225	2190	63452590
Peripheral circulatory failure	29.32	13.55	13	34229	955	63453825
Product use issue	29.32	13.55	46	34196	220474	63234306
Speech disorder	28.71	13.55	66	34176	40563	63414217
Cough	28.68	13.55	73	34169	292670	63162110
Sinus arrest	28.62	13.55	16	34226	1933	63452847
Posture abnormal	28.53	13.55	17	34225	2315	63452465
Sedation	28.49	13.55	64	34178	38745	63416035
Fluid intake reduced	28.39	13.55	20	34222	3621	63451159
Hypernatraemia	27.98	13.55	27	34215	7582	63447198
Stupor	27.70	13.55	21	34221	4254	63450526
Fibromyalgia	27.59	13.55	5	34237	80415	63374365
Cerebral haemorrhage	27.57	13.55	55	34187	30674	63424106
Orthostatic hypotension	26.96	13.55	60	34182	36100	63418680
Anger	26.26	13.55	33	34209	12423	63442357
Bedridden	26.09	13.55	31	34211	11020	63443760
Foreign body	25.92	13.55	16	34226	2322	63452458
Liver function test abnormal	25.38	13.55	70	34172	48111	63406669
Suspiciousness	25.27	13.55	9	34233	370	63454410
Dyspnoea	25.12	13.55	232	34010	661081	62793699
Motor dysfunction	25.09	13.55	30	34212	10731	63444049
Bradykinesia	24.13	13.55	21	34221	5167	63449613
Salivary hypersecretion	24.13	13.55	25	34217	7641	63447139
Vomiting	23.91	13.55	429	33813	559188	62895592
Multiple drug therapy	23.83	13.55	18	34224	3628	63451152
Memory impairment	23.56	13.55	115	34127	104143	63350637
Atrial tachycardia	23.52	13.55	19	34223	4221	63450559
Colitis microscopic	23.38	13.55	27	34215	9312	63445468
Grandiosity	23.37	13.55	8	34234	292	63454488
Melaena	23.33	13.55	51	34191	30314	63424466
Peripheral swelling	23.30	13.55	70	34172	265872	63188908
Prescription drug used without a prescription	23.13	13.55	15	34227	2371	63452409
Hyperhidrosis	22.99	13.55	117	34125	107719	63347061
Chorea	22.95	13.55	13	34229	1611	63453169
Urticaria	22.59	13.55	34	34208	165768	63289012
Hypersexuality	22.47	13.55	9	34233	513	63454267
Social avoidant behaviour	22.34	13.55	16	34226	2972	63451808
Arthritis	22.14	13.55	18	34224	115903	63338877
Pyrexia	22.00	13.55	156	34086	470322	62984458
Hyponatraemic syndrome	21.93	13.55	9	34233	546	63454234
Muscle contracture	21.86	13.55	12	34230	1399	63453381
Skull fracture	21.76	13.55	11	34231	1084	63453696
Food refusal	21.63	13.55	8	34234	367	63454413
Duodenal ulcer perforation	21.57	13.55	10	34232	87199	63367581
Psoriasis	21.47	13.55	10	34232	86947	63367833
Blood cholesterol increased	21.44	13.55	12	34230	94020	63360760
Non-24-hour sleep-wake disorder	21.39	13.55	4	34238	9	63454771
Hyperkalaemia	21.26	13.55	71	34171	54132	63400648
Herbal interaction	21.14	13.55	6	34236	116	63454664
Initial insomnia	21.06	13.55	21	34221	6136	63448644
Brain compression	20.93	13.55	8	34234	402	63454378
Sinoatrial block	20.87	13.55	10	34232	878	63453902
Ill-defined disorder	20.81	13.55	9	34233	81746	63373034
Abnormal dreams	20.81	13.55	27	34215	10489	63444291
Drug level increased	20.76	13.55	41	34201	22695	63432085
Drooling	20.75	13.55	17	34225	3851	63450929
Parkinson's disease	20.65	13.55	11	34231	1208	63453572
Incoherent	20.39	13.55	18	34224	4512	63450268
Adams-Stokes syndrome	20.32	13.55	5	34237	54	63454726
Oropharyngeal pain	20.22	13.55	13	34229	94474	63360306
Supraventricular extrasystoles	20.19	13.55	18	34224	4571	63450209
Haematemesis	19.96	13.55	48	34194	30364	63424416
Chest discomfort	19.87	13.55	18	34224	109951	63344829
Overconfidence	19.58	13.55	3	34239	0	63454780
Affect lability	19.57	13.55	27	34215	11124	63443656
Dysphagia	19.50	13.55	97	34145	88488	63366292
Inflammation	19.49	13.55	10	34232	82263	63372517
Blood pressure decreased	19.45	13.55	78	34164	64944	63389836
Cholesteatoma	19.39	13.55	6	34236	158	63454622
Blister	19.30	13.55	25	34217	129789	63324991
Gastric ulcer	19.18	13.55	41	34201	23996	63430784
Anaphylactic reaction	18.97	13.55	6	34236	66094	63388686
Hypoaesthesia	18.89	13.55	39	34203	168354	63286426
Leukaemoid reaction	18.74	13.55	6	34236	177	63454603
Aphasia	18.44	13.55	49	34193	32951	63421829
Psychotic disorder	18.42	13.55	42	34200	25670	63429110
Emotional poverty	18.31	13.55	7	34235	352	63454428
Executive dysfunction	18.31	13.55	6	34236	191	63454589
Blood pressure orthostatic decreased	18.22	13.55	5	34237	85	63454695
Obsessive thoughts	18.10	13.55	8	34234	583	63454197
Hypertonia	18.09	13.55	17	34225	4620	63450160
Anorgasmia	17.95	13.55	8	34234	595	63454185
Paraesthesia	17.91	13.55	36	34206	156930	63297850
Haematoma	17.76	13.55	50	34192	34770	63420010
Head injury	17.72	13.55	43	34199	27353	63427427
Antisocial behaviour	17.42	13.55	7	34235	402	63454378
Injection site pain	17.31	13.55	27	34215	129773	63325007
Paranoia	17.17	13.55	26	34216	11653	63443127
Intercepted product dispensing error	17.14	13.55	5	34237	107	63454673
Subdural haematoma	17.09	13.55	29	34213	14299	63440481
Ventricular tachycardia	17.02	13.55	35	34207	19944	63434836
Drop attacks	17.01	13.55	8	34234	674	63454106
Dyspepsia	16.99	13.55	18	34224	102178	63352602
Pressure of speech	16.53	13.55	8	34234	718	63454062
Use of accessory respiratory muscles	16.44	13.55	6	34236	265	63454515
Myalgia	16.38	13.55	34	34208	146495	63308285
Blood glucose fluctuation	16.38	13.55	16	34226	4560	63450220
Heart rate increased	16.35	13.55	16	34226	94222	63360558
Labelled drug-drug interaction issue	16.06	13.55	9	34233	1092	63453688
Hepatic function abnormal	15.78	13.55	50	34192	37092	63417688
Duodenal ulcer haemorrhage	15.72	13.55	12	34230	2455	63452325
Overdose	15.63	13.55	111	34131	114967	63339813
Musculoskeletal pain	15.63	13.55	16	34226	92261	63362519
Communication disorder	15.58	13.55	12	34230	2488	63452292
Normal pressure hydrocephalus	15.58	13.55	6	34236	308	63454472
Nasal congestion	15.52	13.55	8	34234	65652	63389128
Acute abdomen	15.52	13.55	10	34232	1563	63453217
Gastric ulcer haemorrhage	15.44	13.55	16	34226	4892	63449888
Product dispensing error	15.23	13.55	23	34219	10282	63444498
Lower gastrointestinal haemorrhage	15.21	13.55	20	34222	7870	63446910
Potentiating drug interaction	15.16	13.55	15	34227	4341	63450439
Neurodegenerative disorder	15.03	13.55	6	34236	339	63454441
Progressive supranuclear palsy	14.92	13.55	4	34238	62	63454718
Opisthotonus	14.84	13.55	6	34236	350	63454430
Inappropriate affect	14.79	13.55	8	34234	906	63453874
Pemphigoid	14.76	13.55	19	34223	7325	63447455
Ataxia	14.60	13.55	28	34214	15167	63439613
Blood urea increased	14.56	13.55	39	34203	26340	63428440
Osteoarthritis	14.54	13.55	18	34224	95325	63359455
Cardiac failure	14.53	13.55	90	34152	89052	63365728
Libido increased	14.39	13.55	9	34233	1336	63453444
Product use in unapproved indication	14.37	13.55	49	34193	179031	63275749
Gastric polyps	14.28	13.55	13	34229	3392	63451388
Disease progression	14.13	13.55	28	34214	122730	63332050
Arrhythmia	14.11	13.55	49	34193	38091	63416689
Theft	14.06	13.55	4	34238	78	63454702
Heat illness	13.98	13.55	5	34237	208	63454572
Neutropenia	13.96	13.55	48	34194	174957	63279823
Asthma	13.92	13.55	30	34212	127531	63327249
Visuospatial deficit	13.90	13.55	3	34239	17	63454763
Delusional disorder, persecutory type	13.78	13.55	5	34237	217	63454563
Thalamus haemorrhage	13.73	13.55	7	34235	702	63454078
Product blister packaging issue	13.69	13.55	5	34237	221	63454559
Poriomania	13.61	13.55	4	34238	88	63454692

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hallucination	366.76	14.34	295	23783	51203	34881650
Fall	345.45	14.34	549	23529	202336	34730517
Dementia	310.81	14.34	163	23915	13585	34919268
Bradycardia	307.95	14.34	316	23762	75102	34857751
Confusional state	304.79	14.34	432	23646	143728	34789125
Delusion	177.97	14.34	110	23968	12525	34920328
Pleurothotonus	164.04	14.34	52	24026	1153	34931700
Agitation	159.43	14.34	197	23881	57202	34875651
Delirium	143.62	14.34	164	23914	43827	34889026
Cognitive disorder	136.79	14.34	131	23947	28562	34904291
Cholinergic syndrome	130.54	14.34	37	24041	550	34932303
Aggression	130.13	14.34	147	23931	38817	34894036
Abnormal behaviour	124.74	14.34	117	23961	24852	34908001
Neuroleptic malignant syndrome	91.41	14.34	85	23993	17849	34915004
Mania	90.78	14.34	65	24013	9446	34923407
Depressed level of consciousness	89.53	14.34	128	23950	42713	34890140
Urinary incontinence	87.71	14.34	85	23993	18789	34914064
Sinus bradycardia	85.22	14.34	71	24007	12892	34919961
Hallucination, visual	84.33	14.34	81	23997	17710	34915143
Somnolence	81.94	14.34	213	23865	110903	34821950
Syncope	79.79	14.34	187	23891	91264	34841589
Amyloid related imaging abnormality-oedema/effusion	74.42	14.34	20	24058	241	34932612
Anal incontinence	71.16	14.34	52	24026	7797	34925056
Sinus node dysfunction	70.19	14.34	41	24037	4208	34928645
Balance disorder	65.92	14.34	108	23970	40546	34892307
Febrile neutropenia	59.78	14.34	11	24067	136838	34796015
Gait disturbance	58.44	14.34	159	23919	84981	34847872
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits	56.98	14.34	15	24063	166	34932687
Blood cholinesterase decreased	54.56	14.34	14	24064	139	34932714
Nightmare	54.43	14.34	58	24020	14333	34918520
Loss of consciousness	54.37	14.34	152	23926	82515	34850338
Orthostatic hypotension	53.47	14.34	77	24001	25842	34907011
Death	52.94	14.34	460	23618	397589	34535264
Memory impairment	50.88	14.34	100	23978	43218	34889635
Pneumonia aspiration	45.94	14.34	94	23984	41809	34891044
Unresponsive to stimuli	45.71	14.34	74	24004	27495	34905358
Poriomania	44.88	14.34	11	24067	89	34932764
Prescribed underdose	44.85	14.34	42	24036	8891	34923962
Parkinsonism	44.24	14.34	40	24038	8098	34924755
Product prescribing issue	44.04	14.34	24	24054	2155	34930698
Disorientation	43.14	14.34	80	23998	33108	34899745
Tremor	41.32	14.34	138	23940	82449	34850404
Libido increased	40.84	14.34	17	24061	834	34932019
Intestinal haemorrhage	40.68	14.34	27	24051	3469	34929384
Blood glucose fluctuation	39.42	14.34	28	24050	4016	34928837
Neutropenia	38.42	14.34	31	24047	156747	34776106
Dyskinesia	38.30	14.34	61	24017	22352	34910501
Arthralgia	37.62	14.34	37	24041	170004	34762849
Dementia with Lewy bodies	36.74	14.34	15	24063	700	34932153
Salivary hypersecretion	36.57	14.34	37	24041	8607	34924246
Hyperhidrosis	36.55	14.34	125	23953	75567	34857286
Bradyarrhythmia	35.81	14.34	21	24057	2170	34930683
Drug abuse	33.76	14.34	13	24065	99083	34833770
Hypersomnia	33.44	14.34	42	24036	12365	34920488
Dementia Alzheimer's type	33.33	14.34	12	24066	396	34932457
Automatism	32.93	14.34	9	24069	116	34932737
Paranoia	32.76	14.34	41	24037	12027	34920826
Serotonin syndrome	32.35	14.34	53	24025	19880	34912973
Muscle rigidity	32.24	14.34	38	24040	10480	34922373
Myoclonus	32.22	14.34	45	24033	14680	34918173
Psychomotor hyperactivity	31.57	14.34	36	24042	9586	34923267
Drug interaction	30.86	14.34	263	23815	225683	34707170
Rhabdomyolysis	30.69	14.34	110	23968	68053	34864800
Extrapyramidal disorder	30.65	14.34	41	24037	12839	34920014
Dizziness	30.18	14.34	255	23823	218266	34714587
Drooling	29.74	14.34	22	24056	3360	34929493
Jealous delusion	28.59	14.34	10	24068	303	34932550
Altered state of consciousness	28.27	14.34	54	24024	22839	34910014
Blood glucose abnormal	28.00	14.34	27	24051	5925	34926928
Electrocardiogram QT prolonged	27.58	14.34	76	24002	40876	34891977
Sexually inappropriate behaviour	27.20	14.34	11	24067	501	34932352
Nonspecific reaction	27.03	14.34	15	24063	1396	34931457
Dehydration	26.77	14.34	167	23911	129802	34803051
Flight of ideas	26.77	14.34	10	24068	367	34932486
Duodenal ulcer	26.31	14.34	34	24044	10298	34922555
Contusion	26.01	14.34	69	24009	36295	34896558
Muscle contractions involuntary	25.72	14.34	16	24062	1840	34931013
Restlessness	25.40	14.34	55	24023	25427	34907426
Dyspnoea	25.39	14.34	154	23924	376628	34556225
Eosinophilic pneumonia chronic	25.32	14.34	9	24069	286	34932567
Gastrointestinal haemorrhage	25.11	14.34	124	23954	88353	34844500
Seizure	24.98	14.34	140	23938	104717	34828136
Lethargy	24.48	14.34	73	24005	41049	34891804
Chorea	24.31	14.34	13	24065	1124	34931729
Pain	24.25	14.34	67	24011	204608	34728245
Atrioventricular block complete	24.25	14.34	31	24047	9288	34923565
Hypothermia	23.74	14.34	33	24045	10715	34922138
Miosis	23.69	14.34	31	24047	9504	34923349
Athetosis	23.53	14.34	6	24072	58	34932795
Dysstasia	23.36	14.34	35	24043	12160	34920693
Daydreaming	22.94	14.34	10	24068	550	34932303
Thrombocytopenia	22.60	14.34	46	24032	156201	34776652
Subdural haematoma	22.59	14.34	46	24032	20375	34912478
Cold sweat	22.56	14.34	31	24047	9956	34922897
Hip fracture	22.53	14.34	34	24044	11891	34920962
Hangover	22.42	14.34	12	24066	1039	34931814
Pruritus	22.11	14.34	40	24038	141941	34790912
Atrioventricular block first degree	22.06	14.34	24	24054	6068	34926785
Gastrointestinal ulcer	21.83	14.34	14	24064	1697	34931156
Femoral neck fracture	21.49	14.34	18	24060	3289	34929564
Atrioventricular block	21.26	14.34	27	24051	8036	34924817
Neuropathy peripheral	20.96	14.34	16	24062	83247	34849606
Inappropriate antidiuretic hormone secretion	20.81	14.34	34	24044	12719	34920134
Behaviour disorder	20.74	14.34	21	24057	4889	34927964
Accidental overdose	20.68	14.34	44	24034	20096	34912757
Neutrophil count decreased	20.46	14.34	5	24073	51099	34881754
Multiple organ dysfunction syndrome	20.20	14.34	14	24064	76552	34856301
Infusion related reaction	19.72	14.34	6	24072	53051	34879802
Skin swelling	19.50	14.34	12	24066	1353	34931500
Mental status changes	19.35	14.34	64	24014	38019	34894834
Executive dysfunction	19.33	14.34	7	24071	235	34932618
Septic shock	19.13	14.34	13	24065	71821	34861032
Potentiating drug interaction	18.71	14.34	20	24058	4957	34927896
Gait inability	18.66	14.34	43	24035	20715	34912138
Speech disorder	18.63	14.34	49	24029	25637	34907216
Intention tremor	18.61	14.34	8	24070	425	34932428
Malignant neoplasm progression	18.49	14.34	20	24058	88026	34844827
Decreased appetite	18.30	14.34	185	23893	166207	34766646
Multiple drug therapy	18.13	14.34	8	24070	453	34932400
Underdose	17.63	14.34	33	24045	13747	34919106
Pyrexia	17.57	14.34	146	23932	332867	34599986
Psoriasis	17.18	14.34	3	24075	38809	34894044
Irritability	16.80	14.34	46	24032	24644	34908209
Urinary tract infection	16.65	14.34	107	23971	83974	34848879
Hiccups	16.62	14.34	27	24051	10055	34922798
Paraesthesia	16.58	14.34	12	24066	64160	34868693
Foaming at mouth	16.44	14.34	9	24069	815	34932038
Defect conduction intraventricular	16.41	14.34	7	24071	365	34932488
Abdominal pain	16.23	14.34	58	24020	163560	34769293
Circulatory collapse	16.15	14.34	41	24037	20997	34911856
Incontinence	16.09	14.34	20	24058	5827	34927026
Leukopenia	15.92	14.34	12	24066	62844	34870009
Stomatitis	15.46	14.34	5	24073	42509	34890344
Paradoxical drug reaction	15.39	14.34	15	24063	3336	34929517
Sudden death	15.36	14.34	33	24045	15168	34917685
Abnormal dreams	14.88	14.34	22	24056	7556	34925297
Chest pain	14.62	14.34	42	24036	126720	34806133
Gastroenteritis pseudomonas	14.61	14.34	4	24074	52	34932801
Impulsive behaviour	14.53	14.34	12	24066	2150	34930703
Urticaria	14.44	14.34	13	24065	62364	34870489

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bradycardia	875.75	13.19	707	49603	134850	79559228
Fall	694.55	13.19	1160	49150	486469	79207609
Dementia	499.67	13.19	264	50046	24395	79669683
Hallucination	429.69	13.19	387	49923	85358	79608720
Syncope	426.55	13.19	545	49765	178904	79515174
Confusional state	390.55	13.19	710	49600	317287	79376791
Sinus bradycardia	335.04	13.19	205	50105	25042	79669036
Agitation	288.91	13.19	335	49975	99380	79594698
Aggression	277.06	13.19	241	50069	50717	79643361
Delusion	268.85	13.19	165	50145	20258	79673820
Delirium	259.81	13.19	293	50017	84334	79609744
Pleurothotonus	259.00	13.19	86	50224	2430	79691648
Electrocardiogram QT prolonged	247.42	13.19	295	50015	90091	79603987
Cognitive disorder	228.20	13.19	250	50060	69676	79624402
Cholinergic syndrome	213.50	13.19	61	50249	1026	79693052
Neuroleptic malignant syndrome	203.87	13.19	156	50154	27403	79666675
Abnormal behaviour	203.50	13.19	175	50135	36246	79657832
Drug interaction	191.53	13.19	636	49674	414547	79279531
Sinus node dysfunction	171.83	13.19	88	50222	7613	79686465
Parkinsonism	168.85	13.19	114	50196	16470	79677608
Somnolence	155.65	13.19	414	49896	238567	79455511
Amyloid related imaging abnormality-oedema/effusion	155.32	13.19	39	50271	388	79693690
Torsade de pointes	148.74	13.19	112	50198	19200	79674878
Mania	143.09	13.19	107	50203	18153	79675925
Depressed level of consciousness	139.28	13.19	232	50078	96420	79597658
Hallucination, visual	137.38	13.19	134	50176	32595	79661483
Muscle rigidity	128.61	13.19	104	50206	19778	79674300
Arthralgia	128.05	13.19	104	50206	571699	79122379
Loss of consciousness	125.96	13.19	307	50003	167636	79526442
Urinary incontinence	124.36	13.19	141	50169	40768	79653310
Seizure	121.73	13.19	326	49984	188508	79505570
Myoclonus	115.63	13.19	113	50197	27547	79666531
Anal incontinence	113.23	13.19	93	50217	18075	79676003
Pain	111.56	13.19	170	50140	703632	78990446
Nightmare	108.76	13.19	106	50204	25755	79668323
Atrioventricular block first degree	108.73	13.19	78	50232	12413	79681665
Femoral neck fracture	104.91	13.19	70	50240	9914	79684164
Tremor	102.00	13.19	286	50024	169797	79524281
Drug ineffective	99.59	13.19	350	49960	1080563	78613515
Extrapyramidal disorder	99.21	13.19	95	50215	22584	79671494
Death	98.24	13.19	652	49658	565862	79128216
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits	94.78	13.19	23	50287	196	79693882
Dehydration	93.38	13.19	356	49954	247831	79446247
Infusion related reaction	89.83	13.19	18	50292	230219	79463859
Joint swelling	89.60	13.19	35	50275	288611	79405467
Disorientation	89.48	13.19	150	50160	62626	79631452
Febrile neutropenia	88.19	13.19	19	50291	230980	79463098
Hypothermia	87.82	13.19	89	50221	22657	79671421
Altered state of consciousness	86.85	13.19	122	50188	43700	79650378
Lethargy	82.76	13.19	168	50142	81124	79612954
Unresponsive to stimuli	79.10	13.19	133	50177	55655	79638423
Dyskinesia	79.03	13.19	118	50192	44655	79649423
Gait disturbance	78.31	13.19	298	50012	207208	79486870
Decreased appetite	75.68	13.19	420	49890	341998	79352080
Pneumonia aspiration	74.93	13.19	144	50166	66823	79627255
Electrocardiogram PR prolongation	73.08	13.19	30	50280	1553	79692525
Mental status changes	72.50	13.19	142	50168	66817	79627261
Hypersensitivity	71.71	13.19	38	50272	262201	79431877
Arthropathy	68.75	13.19	14	50296	177097	79516981
Rheumatoid arthritis	68.53	13.19	23	50287	208447	79485631
Atrioventricular block complete	67.82	13.19	67	50243	16543	79677535
Restlessness	67.46	13.19	112	50198	46380	79647698
Orthostatic hypotension	66.84	13.19	124	50186	56040	79638038
Dizziness	65.73	13.19	561	49749	525880	79168198
Sexually inappropriate behaviour	65.70	13.19	21	50289	524	79693554
Rash	65.42	13.19	170	50140	578188	79115890
Sinusitis	65.27	13.19	21	50289	195480	79498598
Psychomotor hyperactivity	65.18	13.19	66	50244	16783	79677295
Dementia with Lewy bodies	64.10	13.19	23	50287	823	79693255
Dementia Alzheimer's type	63.53	13.19	24	50286	995	79693083
Drug hypersensitivity	62.37	13.19	58	50252	298858	79395220
Immobile	61.74	13.19	44	50266	6929	79687149
Swelling	61.33	13.19	30	50280	216681	79477397
Sudden death	60.74	13.19	73	50237	22438	79671640
Hyperhidrosis	59.99	13.19	221	50089	151271	79542807
Pruritus	59.83	13.19	98	50212	394550	79299528
Circulatory collapse	59.07	13.19	94	50216	37574	79656504
Gastrointestinal haemorrhage	58.91	13.19	216	50094	147503	79546575
Systemic lupus erythematosus	57.85	13.19	5	50305	121144	79572934
Drug intolerance	57.79	13.19	49	50261	264070	79430008
Accidental overdose	56.95	13.19	95	50215	39486	79654592
Urinary tract infection	56.19	13.19	330	49980	274182	79419896
Miosis	55.94	13.19	59	50251	15730	79678348
Salivary hypersecretion	55.53	13.19	56	50254	14168	79679910
Hypophagia	55.03	13.19	101	50209	45266	79648812
Pain in extremity	54.81	13.19	91	50219	364447	79329631
Medication error	54.10	13.19	128	50182	68514	79625564
Urinary retention	54.06	13.19	114	50196	56516	79637562
Rhabdomyolysis	53.71	13.19	165	50145	102966	79591112
Alopecia	53.01	13.19	41	50269	231314	79462764
Atrioventricular block	52.49	13.19	54	50256	13987	79680091
Poriomania	50.61	13.19	14	50296	208	79693870
Cerebral infarction	49.60	13.19	97	50213	45579	79648499
Torticollis	49.58	13.19	26	50284	2361	79691717
Treatment failure	49.15	13.19	23	50287	170463	79523615
Hip fracture	48.56	13.19	77	50233	30684	79663394
Stomatitis	48.56	13.19	16	50294	146741	79547337
Bradyarrhythmia	48.27	13.19	31	50279	4115	79689963
Off label use	48.27	13.19	355	49955	906860	78787218
Glossodynia	47.39	13.19	5	50305	103332	79590746
Neutropenia	46.88	13.19	68	50242	287642	79406436
Weight increased	46.75	13.19	64	50246	277322	79416756
Wandering pacemaker	46.48	13.19	8	50302	6	79694072
Neuropsychiatric symptoms	46.22	13.19	21	50289	1394	79692684
Generalised tonic-clonic seizure	46.17	13.19	92	50218	43818	79650260
Headache	46.14	13.19	234	50076	653538	79040540
Cerebral atrophy	45.49	13.19	39	50271	8036	79686042
Blood glucose fluctuation	45.44	13.19	36	50274	6646	79687432
Apathy	45.10	13.19	48	50262	12929	79681149
Memory impairment	45.06	13.19	164	50146	111570	79582508
Hypokalaemia	44.87	13.19	195	50115	143845	79550233
Dyspnoea	44.79	13.19	337	49973	856688	78837390
Paranoia	44.42	13.19	58	50252	19374	79674704
Fracture	43.64	13.19	61	50249	21740	79672338
Reduced facial expression	43.31	13.19	25	50285	2740	79691338
Blood cholinesterase decreased	43.01	13.19	13	50297	268	79693810
Incontinence	41.65	13.19	48	50262	14116	79679962
Nasopharyngitis	41.36	13.19	60	50250	253821	79440257
Jealous delusion	40.96	13.19	13	50297	317	79693761
Infection	40.49	13.19	56	50254	241656	79452422
Contraindicated product administered	39.94	13.19	25	50285	157513	79536565
Epilepsy	39.86	13.19	83	50227	40777	79653301
Paraesthesia	39.43	13.19	32	50278	176291	79517787
Libido increased	39.31	13.19	21	50289	1980	79692098
Cough	39.00	13.19	111	50199	366678	79327400
Balance disorder	38.93	13.19	144	50166	98713	79595365
Pyrexia	38.76	13.19	260	50050	678449	79015629
Behaviour disorder	38.67	13.19	32	50278	6281	79687797
Hepatic enzyme increased	38.57	13.19	35	50275	182575	79511503
Pemphigus	38.37	13.19	8	50302	99574	79594504
Drooling	38.28	13.19	31	50279	5903	79688175
Encephalopathy	38.08	13.19	111	50199	67286	79626792
Executive dysfunction	37.95	13.19	12	50298	289	79693789
Product prescribing issue	36.91	13.19	26	50284	4019	79690059
Multiple drug therapy	36.72	13.19	26	50284	4052	79690026
Intentional product use issue	36.06	13.19	26	50284	152086	79541992
Hypocapnia	35.99	13.19	14	50296	629	79693449
Listless	35.66	13.19	25	50285	3836	79690242
Posture abnormal	35.63	13.19	25	50285	3841	79690237
Urticaria	35.11	13.19	39	50271	185162	79508916
Sedation	34.80	13.19	91	50219	51804	79642274
Malignant neoplasm progression	33.90	13.19	22	50288	135968	79558110
Impaired healing	33.86	13.19	7	50303	87648	79606430
Subdural haematoma	33.21	13.19	66	50244	31368	79662710
Thrombocytopenia	33.05	13.19	74	50236	265185	79428893
Speech disorder	33.02	13.19	92	50218	54353	79639725
Helicobacter infection	32.94	13.19	3	50307	69701	79624377
Psoriasis	32.90	13.19	8	50302	89579	79604499
Therapeutic product effect decreased	32.75	13.19	33	50277	163830	79530248
Abnormal dreams	32.42	13.19	38	50272	11374	79682704
Upper gastrointestinal haemorrhage	32.42	13.19	77	50233	41303	79652775
Lower respiratory tract infection	32.08	13.19	21	50289	129199	79564879
Mucosal inflammation	31.43	13.19	5	50305	75575	79618503
Tardive dyskinesia	31.38	13.19	36	50274	10535	79683543
Parkinson's disease	31.32	13.19	17	50293	1654	79692424
Melaena	31.30	13.19	97	50213	60793	79633285
Social avoidant behaviour	30.74	13.19	25	50285	4789	79689289
Hypersomnia	30.04	13.19	53	50257	23033	79671045
Automatism	29.94	13.19	9	50301	182	79693896
Nonspecific reaction	29.65	13.19	19	50291	2513	79691565
Arthritis	29.43	13.19	18	50292	114862	79579216
Musculoskeletal pain	29.20	13.19	14	50296	102340	79591738
Paratonia	28.99	13.19	6	50304	22	79694056
Neuroglycopenia	28.73	13.19	11	50299	473	79693605
Duodenal ulcer	28.67	13.19	43	50267	16326	79677752
Sialoadenitis	28.47	13.19	17	50293	1984	79692094
Bradykinesia	28.39	13.19	30	50280	8013	79686065
Peripheral circulatory failure	28.21	13.19	14	50296	1132	79692946
Oropharyngeal pain	28.20	13.19	17	50293	109336	79584742
Hypomania	28.17	13.19	29	50281	7515	79686563
Abdominal discomfort	28.04	13.19	74	50236	250653	79443425
Hypotension	27.97	13.19	411	49899	439906	79254172
Duodenal ulcer haemorrhage	27.59	13.19	28	50282	7135	79686943
Bedridden	27.53	13.19	36	50274	12043	79682035
Fibromyalgia	27.34	13.19	4	50306	64336	79629742
Injection site pain	27.28	13.19	25	50285	129813	79564265
Adams-Stokes syndrome	27.23	13.19	8	50302	149	79693929
Muscle contractions involuntary	27.15	13.19	21	50289	3744	79690334
Neuropathy peripheral	26.51	13.19	30	50280	141275	79552803
Dysphagia	26.36	13.19	149	50161	121987	79572091
Drop attacks	26.30	13.19	13	50297	1042	79693036
Anaphylactic reaction	26.21	13.19	10	50300	83733	79610345
Potentiating drug interaction	26.12	13.19	30	50280	8789	79685289
Blood pressure decreased	26.04	13.19	128	50182	99338	79594740
Hypoaesthesia	25.79	13.19	46	50264	179306	79514772
Product use issue	25.75	13.19	59	50251	209763	79484315
Pelvic fracture	25.70	13.19	35	50275	12169	79681909
Flight of ideas	25.67	13.19	12	50298	850	79693228
Chorea	25.52	13.19	17	50293	2400	79691678
Gastric ulcer	25.39	13.19	62	50248	33843	79660235
Cerebral haemorrhage	25.25	13.19	87	50223	57586	79636492
Chest discomfort	25.15	13.19	30	50280	138014	79556064
Fluid intake reduced	24.99	13.19	25	50285	6263	79687815
Daydreaming	24.77	13.19	12	50298	921	79693157
Pressure of speech	24.44	13.19	13	50297	1215	79692863
Long QT syndrome	24.27	13.19	24	50286	5931	79688147
Fatigue	24.25	13.19	427	49883	929300	78764778
Incoherent	24.20	13.19	27	50283	7665	79686413
Lack of spontaneous speech	24.09	13.19	8	50302	226	79693852
Haematemesis	23.90	13.19	80	50230	52184	79641894
Neutrophil count decreased	23.69	13.19	15	50295	93944	79600134
Irritability	23.46	13.19	68	50242	41076	79653002
Sinoatrial block	23.28	13.19	13	50297	1338	79692740
Anger	23.11	13.19	40	50270	17122	79676956
Dysarthria	22.95	13.19	94	50216	67528	79626550
Hyponatraemia	22.87	13.19	191	50119	177657	79516421
Superficial siderosis of central nervous system	22.58	13.19	5	50305	27	79694051
Hypernatraemia	22.57	13.19	36	50274	14415	79679663
Motor dysfunction	22.05	13.19	36	50274	14697	79679381
Cerebrovascular accident	21.71	13.19	170	50140	155122	79538956
Product use in unapproved indication	21.60	13.19	83	50227	250276	79443802
Vomiting	21.57	13.19	561	49749	665267	79028811
Wrong patient received product	21.44	13.19	20	50290	4598	79689480
Sinus arrest	21.44	13.19	18	50292	3604	79690474
Myalgia	21.35	13.19	54	50256	185587	79508491
Eosinophilic pneumonia chronic	21.17	13.19	9	50301	509	79693569
Dropped head syndrome	21.12	13.19	8	50302	334	79693744
Nasal congestion	21.04	13.19	11	50299	76541	79617537
Back pain	20.75	13.19	110	50200	304070	79390008
Cold sweat	20.65	13.19	40	50270	18659	79675419
Foreign body	20.56	13.19	16	50294	2878	79691200
Food refusal	20.49	13.19	9	50301	551	79693527
Dyspepsia	20.47	13.19	23	50287	108664	79585414
Wound	20.37	13.19	26	50284	116153	79577925
Affect lability	20.33	13.19	30	50280	11229	79682849
Gastrointestinal ulcer	20.14	13.19	17	50293	3429	79690649
Prescribed underdose	20.04	13.19	52	50258	29462	79664616
Dysstasia	19.99	13.19	50	50260	27696	79666382
Erythema	19.93	13.19	73	50237	223217	79470861
Obsessive thoughts	19.80	13.19	11	50299	1121	79692957
Cholesteatoma	19.79	13.19	6	50304	125	79693953
Inflammation	19.75	13.19	18	50292	93735	79600343
Pemphigoid	19.72	13.19	35	50275	15280	79678798
Drug reaction with eosinophilia and systemic symptoms	19.56	13.19	8	50302	64236	79629842
Supraventricular extrasystoles	19.41	13.19	23	50287	6964	79687114
Suspiciousness	19.25	13.19	9	50301	638	79693440
Gastric ulcer haemorrhage	19.18	13.19	26	50284	9001	79685077
Discomfort	19.18	13.19	31	50279	125586	79568492
Blood cholesterol increased	18.95	13.19	15	50295	83705	79610373
Disease progression	18.69	13.19	57	50253	184305	79509773
Colitis microscopic	18.45	13.19	28	50282	10740	79683338
Accidental exposure to product by child	18.27	13.19	15	50295	2911	79691167
Heart rate increased	18.23	13.19	30	50280	120694	79573384
Hypersexuality	18.18	13.19	12	50298	1668	79692410
Osteoarthritis	18.11	13.19	17	50293	87292	79606786
Septic shock	18.10	13.19	31	50279	122770	79571308
Stupor	18.07	13.19	22	50288	6850	79687228
Injection site reaction	18.07	13.19	6	50304	54779	79639299
Haematoma	18.06	13.19	73	50237	52122	79641956
Intention tremor	18.03	13.19	9	50301	737	79693341
Hangover	17.95	13.19	13	50297	2099	79691979
Bone marrow failure	17.93	13.19	5	50305	51102	79642976
Head injury	17.80	13.19	58	50252	37311	79656767
Hyponatraemic syndrome	17.65	13.19	9	50301	771	79693307
Communication disorder	17.63	13.19	17	50293	4073	79690005
Intestinal haemorrhage	17.60	13.19	21	50289	6405	79687673
Skull fracture	17.55	13.19	12	50298	1768	79692310
Normal pressure hydrocephalus	17.55	13.19	8	50302	535	79693543
Duodenal ulcer perforation	17.49	13.19	10	50300	66201	79627877
Flushing	17.37	13.19	18	50292	88250	79605828
Pain in jaw	17.18	13.19	4	50306	46147	79647931
Peripheral swelling	17.03	13.19	100	50210	269517	79424561
Atrioventricular block second degree	16.98	13.19	22	50288	7290	79686788
Grandiosity	16.95	13.19	8	50302	579	79693499
Brain compression	16.94	13.19	8	50302	580	79693498
Hypoglycaemia	16.94	13.19	116	50194	101478	79592600
Bone pain	16.88	13.19	7	50303	55735	79638343
Asthma	16.56	13.19	38	50272	135057	79559021
COVID-19	16.52	13.19	48	50262	157626	79536452
Injection site erythema	16.49	13.19	15	50295	78182	79615896
Product blister packaging issue	16.48	13.19	6	50304	224	79693854
Apraxia	16.46	13.19	14	50296	2853	79691225
Herpes zoster	16.14	13.19	21	50289	93062	79601016
Lower gastrointestinal haemorrhage	16.01	13.19	33	50277	16092	79677986
Stress	15.94	13.19	16	50294	79596	79614482
Aphasia	15.88	13.19	65	50245	46667	79647411
Senile dementia	15.78	13.19	6	50304	253	79693825
Hiccups	15.68	13.19	25	50285	10006	79684072
Lacunar infarction	15.55	13.19	19	50291	5938	79688140
Rapid eye movement sleep behaviour disorder	15.49	13.19	7	50303	459	79693619
Non-24-hour sleep-wake disorder	15.48	13.19	4	50306	45	79694033
Thalamus haemorrhage	15.21	13.19	11	50299	1771	79692307
Blister	15.14	13.19	33	50277	119443	79574635
Injection site pruritus	15.09	13.19	4	50306	42279	79651799
Labelled drug-drug interaction issue	15.07	13.19	10	50300	1403	79692675
Neurodegenerative disorder	15.05	13.19	7	50303	490	79693588
Therapeutic product effect incomplete	14.93	13.19	43	50267	141602	79552476
Candida infection	14.86	13.19	3	50307	38211	79655867
Defect conduction intraventricular	14.84	13.19	7	50303	506	79693572
Serotonin syndrome	14.81	13.19	62	50248	44965	79649113
Ventricular tachycardia	14.79	13.19	59	50251	41876	79652202
Initial insomnia	14.77	13.19	20	50290	6918	79687160
Blood glucose abnormal	14.72	13.19	25	50285	10541	79683537
Abdominal pain	14.70	13.19	166	50144	389403	79304675
Atrial fibrillation	14.68	13.19	190	50120	197696	79496382
Intercepted product dispensing error	14.58	13.19	5	50305	156	79693922
Gastroenteritis pseudomonas	14.36	13.19	4	50306	61	79694017
Dry eye	14.15	13.19	3	50307	36928	79657150
Wheezing	14.15	13.19	33	50277	116631	79577447
Gait inability	14.14	13.19	74	50236	58843	79635235
Coma scale abnormal	14.08	13.19	22	50288	8656	79685422
Leukaemoid reaction	13.94	13.19	6	50304	350	79693728
Acute psychosis	13.71	13.19	15	50295	4165	79689913
Anaphylactic shock	13.64	13.19	3	50307	35993	79658085
Psychotic disorder	13.61	13.19	57	50253	41345	79652733
Hip arthroplasty	13.51	13.19	3	50307	35753	79658325
Ill-defined disorder	13.46	13.19	13	50297	65862	79628216
Decreased interest	13.42	13.19	14	50296	3683	79690395
Drug resistance	13.27	13.19	5	50305	42208	79651870
Gastric polyps	13.27	13.19	14	50296	3733	79690345
Oesophageal ulcer	13.19	13.19	19	50291	6956	79687122

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06DA02	NERVOUS SYSTEM PSYCHOANALEPTICS ANTI-DEMENTIA DRUGS Anticholinesterases
ATC	N06DA52	NERVOUS SYSTEM PSYCHOANALEPTICS ANTI-DEMENTIA DRUGS Anticholinesterases
ATC	N06DA53	NERVOUS SYSTEM PSYCHOANALEPTICS ANTI-DEMENTIA DRUGS Anticholinesterases
FDA MoA	N0000000177	Cholinesterase Inhibitors
CHEBI has role	CHEBI:38462	acetylcholinesterase inhibitors
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D002800	Cholinesterase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018697	Nootropic Agents
FDA EPC	N0000175723	Cholinesterase Inhibitor
CHEBI has role	CHEBI:37733	EC 3.1.1.8 inhibitor
CHEBI has role	CHEBI:66980	intelligence enhancer

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Alzheimer's disease	indication	26929004	DOID:10652
Moderate to Severe Alzheimer's Type Dementia	indication
Diffuse Lewy body disease	off-label use	80098002
Sick sinus syndrome	contraindication	36083008	DOID:13884
Gastrointestinal ulcer	contraindication	40845000
Sinus bradycardia	contraindication	49710005
Gastrointestinal hemorrhage	contraindication	74474003
Epilepsy	contraindication	84757009	DOID:1826
Asthma	contraindication	195967001	DOID:2841
Atrioventricular block	contraindication	233917008	DOID:0050820
Bladder outflow obstruction	contraindication	236645006
NSAID-Induced Gastric Ulcer	contraindication
Chronic Obstructive Pulmonary Disease with Bronchospasms	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.4	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10MG;14MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8173708	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8283379	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8338486	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8362085	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580858	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8173708	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8283379	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8338486	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8362085	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580858	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8173708	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8283379	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8338486	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8362085	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580858	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8173708	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8283379	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8338486	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8362085	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580858	Nov. 22, 2025	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8039009	March 24, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;14MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8058291	Dec. 5, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;21MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8058291	Dec. 5, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;28MG	NAMZARIC	ABBVIE	N206439	Dec. 23, 2014	RX	CAPSULE, EXTENDED RELEASE	ORAL	8058291	Dec. 5, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG;7MG	NAMZARIC	ABBVIE	N206439	July 18, 2016	RX	CAPSULE, EXTENDED RELEASE	ORAL	8058291	Dec. 5, 2029	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG/DAY	ADLARITY	CORIUM	N212304	March 11, 2022	RX	SYSTEM	TRANSDERMAL	11679086	May 26, 2037	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
5MG/DAY	ADLARITY	CORIUM	N212304	March 11, 2022	RX	SYSTEM	TRANSDERMAL	11679086	May 26, 2037	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG/DAY	ADLARITY	CORIUM	N212304	March 11, 2022	RX	SYSTEM	TRANSDERMAL	10016372	July 26, 2037	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG/DAY	ADLARITY	CORIUM	N212304	March 11, 2022	RX	SYSTEM	TRANSDERMAL	11103463	July 26, 2037	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
5MG/DAY	ADLARITY	CORIUM	N212304	March 11, 2022	RX	SYSTEM	TRANSDERMAL	10016372	July 26, 2037	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
5MG/DAY	ADLARITY	CORIUM	N212304	March 11, 2022	RX	SYSTEM	TRANSDERMAL	11103463	July 26, 2037	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG/DAY	ADLARITY	CORIUM	N212304	March 11, 2022	RX	SYSTEM	TRANSDERMAL	11648214	Sept. 23, 2037	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
5MG/DAY	ADLARITY	CORIUM	N212304	March 11, 2022	RX	SYSTEM	TRANSDERMAL	11648214	Sept. 23, 2037	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG/DAY	ADLARITY	CORIUM	N212304	March 11, 2022	RX	SYSTEM	TRANSDERMAL	10835499	May 20, 2038	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
5MG/DAY	ADLARITY	CORIUM	N212304	March 11, 2022	RX	SYSTEM	TRANSDERMAL	10835499	May 20, 2038	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
10MG/DAY	ADLARITY	CORIUM	N212304	March 11, 2022	RX	SYSTEM	TRANSDERMAL	10966936	Aug. 11, 2038	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMERS TYPE
5MG/DAY	ADLARITY	CORIUM	N212304	March 11, 2022	RX	SYSTEM	TRANSDERMAL	10966936	Aug. 11, 2038	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMERS TYPE

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
10MG/DAY	ADLARITY	CORIUM	N212304	March 11, 2022	RX	SYSTEM	TRANSDERMAL	March 11, 2025	NEW PRODUCT
5MG/DAY	ADLARITY	CORIUM	N212304	March 11, 2022	RX	SYSTEM	TRANSDERMAL	March 11, 2025	NEW PRODUCT

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN	INHIBITOR	Ki	7.80	WOMBAT-PK	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5.70	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	4.46	CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.05	WOMBAT-PK
Amine oxidase [flavin-containing] B	Enzyme	P27338	AOFB_HUMAN		IC50	4.82	CHEMBL
Cholinesterase	Enzyme	P06276	CHLE_HUMAN		Ki	4.90	CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Enzyme	Q08499	PDE4D_HUMAN		IC50	4.44	CHEMBL
Acetylcholine receptor subunit epsilon	Ion channel	Q04844	ACHE_HUMAN		IC50	7.49	CHEMBL
Histamine H3 receptor	GPCR	Q9Y5N1	HRH3_HUMAN		IC50	6.46	CHEMBL
Beta-secretase 1	Enzyme	P56817	BACE1_HUMAN		IC50	5.49	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.84	CHEMBL
Acetylcholinesterase	Enzyme		ACES_TORCA		IC50	8.24	CHEMBL
Acetylcholinesterase	Enzyme		ACES_MOUSE		IC50	8.24	CHEMBL
Butyrylcholinesterase; Protein Bche	Enzyme		Q9JKC1_RAT		IC50	5.56	CHEMBL
Acetylcholinesterase	Enzyme		ACES_RAT		IC50	8.77	CHEMBL
Acetylcholinesterase	Enzyme		ACES_ELEEL		Ki	7.25	CHEMBL
Acetylcholinesterase	Enzyme		ACES_BOVIN		Ki	8.54	CHEMBL
Choline O-acetyltransferase	Enzyme		CLAT_RAT		IC50	8.28	CHEMBL
Amine oxidase [flavin-containing] B	Enzyme		AOFB_RAT		IC50	4.82	CHEMBL
Cholinesterase	Enzyme		CHLE_MOUSE		IC50	5.15	CHEMBL
Butyrylcholinesterase	Enzyme		Q9N1N9_HORSE		Ki	6.19	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane other		SGMR1_CAVPO		Ki	7.84	CHEMBL
Cholinesterase	Enzyme		CHLE_HORSE		IC50	6.08	CHEMBL

External reference:

ID	Source
D00670	KEGG_DRUG
120011-70-3	SECONDARY_CAS_RN
4021006	VANDF
4024045	VANDF
C0527316	UMLSCUI
CHEBI:53289	CHEBI
E20	PDB_CHEM_ID
CHEMBL502	ChEMBL_ID
CHEMBL1678	ChEMBL_ID
DB00843	DRUGBANK_ID
D000077265	MESH_DESCRIPTOR_UI
3152	PUBCHEM_CID
6599	IUPHAR_LIGAND_ID
7517	INN_ID
870555-76-3	SECONDARY_CAS_RN
8SSC91326P	UNII
135446	RXNORM
15004	MMSL
178540	MMSL
4631	MMSL
6432	MMSL
d04099	MMSL
006295	NDDF
006296	NDDF
108497001	SNOMEDCT_US
386855006	SNOMEDCT_US
386856007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9747	TABLET, FILM COATED	5 mg	ORAL	ANDA	24 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9748	TABLET, FILM COATED	10 mg	ORAL	ANDA	24 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1207	CAPSULE	10 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1207	CAPSULE	10 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1214	CAPSULE	10 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1214	CAPSULE	10 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1221	CAPSULE	10 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1221	CAPSULE	10 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1228	CAPSULE	10 mg	ORAL	NDA	31 sections
Namzaric	HUMAN PRESCRIPTION DRUG LABEL	2	0456-1228	CAPSULE	10 mg	ORAL	NDA	31 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7951	TABLET, FILM COATED	5 mg	ORAL	ANDA	18 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7952	TABLET, FILM COATED	10 mg	ORAL	ANDA	18 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8313	TABLET, FILM COATED	10 mg	ORAL	ANDA	19 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5276	TABLET, ORALLY DISINTEGRATING	5 mg	ORAL	ANDA	26 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-5277	TABLET, ORALLY DISINTEGRATING	10 mg	ORAL	ANDA	26 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6477	TABLET, FILM COATED	5 mg	ORAL	ANDA	24 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6478	TABLET, FILM COATED	10 mg	ORAL	ANDA	24 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-102	TABLET, FILM COATED	5 mg	ORAL	ANDA	25 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-102	TABLET, FILM COATED	5 mg	ORAL	ANDA	25 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-103	TABLET, FILM COATED	10 mg	ORAL	ANDA	25 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	13668-103	TABLET, FILM COATED	10 mg	ORAL	ANDA	25 sections
Donepezil Hydrochloride	Human Prescription Drug Label	1	16571-778	TABLET, FILM COATED	5 mg	ORAL	ANDA	26 sections
Donepezil Hydrochloride	Human Prescription Drug Label	1	16571-779	TABLET, FILM COATED	10 mg	ORAL	ANDA	26 sections
DONEPEZIL HYDROCHLORIDE	Human Prescription Drug Label	1	24724-028	TABLET, FILM COATED	5 mg	ORAL	ANDA	25 sections
DONEPEZIL HYDROCHLORIDE	Human Prescription Drug Label	1	24724-029	TABLET, FILM COATED	10 mg	ORAL	ANDA	25 sections
Donepezil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	24979-004	TABLET, FILM COATED	23 mg	ORAL	ANDA	16 sections
donepezil hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	29300-248	TABLET, FILM COATED	5 mg	ORAL	ANDA	23 sections
donepezil hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	29300-249	TABLET, FILM COATED	10 mg	ORAL	ANDA	23 sections
donepezil hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	29300-250	TABLET, ORALLY DISINTEGRATING	5 mg	ORAL	ANDA	23 sections
donepezil hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	29300-251	TABLET, ORALLY DISINTEGRATING	10 mg	ORAL	ANDA	23 sections